Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - dienogest 2 mg; ethinylestradiol 0,03 mg - film-coated tablet - 2 mg - 0,03 mg - ethinylestradiol 0.03 mg; dienogest 2 mg - antiandrogens and estrogens; g03aa16 dienogest and ethinylestradiol

Philippines - English - FDA (Food And Drug Administration)

eliset pharmaceutical, inc. - isopropyl alcohol - solution - 70%(v/v)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mithra pharmaceuticals sa-nv - ethinylestradiol 0,03 mg; dienogest 2 mg - film-coated tablet - antiandrogens and estrogens; g03aa16 dienogest and ethinylestradiol

United States - English - NLM (National Library of Medicine)

louisville distilling company, llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. • in children less than 2 months of age • on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition

Malta - English - Medicines Authority

laboratoires thea 12 rue louis blériot, 63017 clermont-ferrand cedex 2, france - dexamethasone sodium, phosphate, chloramphenicol - eye drops, solution - dexamethasone sodium phosphate 1 mg/ml chloramphenicol 5 mg/ml - ophthalmologicals

Malta - English - Medicines Authority

laboratoires thea 12 rue louis blériot, 63017 clermont-ferrand cedex 2, france - antazoline hydrochloride, tetryzoline hydrochloride - eye drops, solution - antazoline hydrochloride 0.5 mg/ml tetryzoline hydrochloride 0.4 mg/ml - ophthalmologicals

Malta - English - Medicines Authority

laboratoires thea 12 rue louis blériot, 63017 clermont-ferrand cedex 2, france - diclofenac sodium - eye drops, solution - diclofenac sodium 1 mg/ml - ophthalmologicals

Malta - English - Medicines Authority

laboratoires thea 12 rue louis blériot, 63017 clermont-ferrand cedex 2, france - ketotifen - eye drops, solution - ketotifen 0.25 mg/ml - ophthalmologicals

United States - English - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 300 mci in 1 ml - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d

United States - English - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d